Coral Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical formulations. The Company is engaged in the manufacturing of generic - branded, nutraceuticals, over the counter (OTC), and herbal medicines. It offers dosage forms, which include tablets, capsules, liquid orals, injections (liquids and powder), ointment and creams, gels and lotions, and suppositories. Its product categories include nutraceutical, OTC, sterile and non-sterile. Its nutraceutical products include DAX 200, DAX 400 Drops, Zest drops, and Super Zestcal Tablets. Its OTC products include herbal range, skin care, medical devices, and effervescent range. Its sterile products include small volume liquid - injectables, lyophilized range - injectables, eye drops, and eardrops. Its non-sterile antibiotics/antibacterials, antifungals, gastro-intestinal drugs, anti-emetics, and muscle relaxants. The Company also exports its products to various countries.
CORAL LABORATORIES LTD. Financial Highlights
- Revenue: CORAL LABORATORIES LTD. reported revenue of ₹95.80 crore in FY26 vs ₹124.12 crore in FY25. It showed a decrease of 22.82% on a yearly basis.
- Operating Profit: CORAL LABORATORIES LTD. reported an operating profit of ₹23.11 crore in FY26 vs ₹32.47 crore in FY25. It showed a decrease of 28.83% on a year-on-year basis.
- Net Profit: CORAL LABORATORIES LTD. reported a net profit of ₹16.38 crore in FY26 vs ₹24.16 crore in FY25. It showed a decrease of 32.20% on a yearly basis.
CORAL LABORATORIES LTD. Quarterly Result Highlights
- CORAL LABORATORIES LTD. reported revenue of ₹29.13 crore in Mar 2026, compared with ₹24.05 crore in Dec 2025, representing an increase of 21.12% on a quarter-on-quarter (QoQ) basis.
- CORAL LABORATORIES LTD. reported an operating profit of ₹8.29 crore in Mar 2026, compared with ₹3.70 crore in Dec 2025, representing an increase of 124.05% on a quarter-on-quarter (QoQ) basis.
- CORAL LABORATORIES LTD. reported a profit of ₹5.22 crore in Mar 2026, compared with ₹2.78 crore in Dec 2025, reflecting an increase of 87.77% on a QoQ basis.
- The earnings per share (EPS) of CORAL LABORATORIES LTD. stood at ₹67.61 during Mar 2026.